Skip to main content

Peer Review reports

From: The role of anti-IgE (omalizumab/Xolair) in the management of severe recalcitrant paediatric atopic eczema (ADAPT): statistical analysis plan

Original Submission
28 Sep 2016 Submitted Original manuscript
10 Feb 2017 Reviewed Reviewer Report - Cristina Martín-Arriscado
27 Apr 2017 Author responded Author comments - Tao Chen
Resubmission - Version 2
27 Apr 2017 Submitted Manuscript version 2
4 May 2017 Editorially accepted
23 May 2017 Article published 10.1186/s13063-017-1976-6

You can find further information about peer review here.

Back to article page